- Cystic fibrosis,
Cystic fibrosis (CF), a genetic disease affecting the lungs and Gl tract, is the second most common disease leading to shortened life spans in children. As a result of disease pathology, patients experience frequent lung infections along with nausea, loss of appetite, and poor absorption of nutrients. Current treatment for these infections involves continuous or intermittent IV meropenem therapy. One frequent side effect of meropenem in cystic fibrosis patients is nausea, vomiting, and diarrhea, leading to further weight loss in these patients. It is hypothesized that increased serum concentrations of meropenem lead to increased incidences of the Gl side effects, and that continuous IV administration of meropenem will reduce nausea when compared to intermittent administration. This collaborative project with Dayton Children's Hospital, to be completed in the spring of 2015, proposes to improve the quality of life and care for pediatric CF patients by assessing reported nausea and its relationship to serum concentration of meropenem as well as testing established clinical protocols for meropenem administration in pediatric CF patients admitted to Dayton Children's. A crossover design will be used, with patients randomly divided into two treatment groups. One group will receive four days of a 120 mg/kg/day continuous IV dose of meropenem followed by an intermittent 40 mg/kg/dose infused over 30 minutes every eight hours for another four days. The other group will receive the intermittent dose followed by the continuous infusion. Serum concentrations will be quantified utilizing a High Pressure Liquid Chromatography instrument and incidence of nausea will be measured through the average doses of kytril, an antiemetic, ordered for each patient in addition to the number of episodes of emesis. This study will be carried out with around 10 participants in order to provide a framework for further multi-site studies of the same nature.
Available at: http://works.bepress.com/juanita-draime/3/